Search

Displaying results 3201 - 3210 of 10000 in total
  1. Drug

    Andusomeran

    go.drugbank.com/drugs/DB18227
    ApprovedInvestigational

    Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. … [elasomeran], [imelasomeran]), but is designed to be effective against the Omicron XBB.1.5 subvariant.

  2. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    [L53158] The c-Met protein is found to be overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients and is associated with poor prognosis and limited treatment options. … [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment

  3. Drug

    Lumefantrine

    go.drugbank.com/drugs/DB06708
    ApprovedInvestigational

    Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

  4. Drug

    DL-Methylephedrine

    go.drugbank.com/drugs/DB11278
    Approved

    The abuse of methylephedrine-containing medications has been reported in Japan. Methylephedrine is not legally available in the United States, but has been identified in cases of drug abuse [L2836]. … Methylephedrine is a sympathomimetic amine that appears in various over-the-counter cough and cold medications throughout the world [L2838], [L2839], [L2840].

    Synonyms: (+/-)-N-methylephedrine, N-methylephedrine DL-form
  5. Drug

    JPC-3210

    go.drugbank.com/drugs/DB15609
    Experimental

    It is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant _Plasmodium falciparum_ lines, low cytotoxicity, potent in vivo efficacy against murine malaria … JPC-3210 is a potent antimalarial agent.

  6. Drug

    Imgatuzumab

    go.drugbank.com/drugs/DB14884
    Investigational

    Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With

  7. Drug

    Romiplostim

    go.drugbank.com/drugs/DB05332
    ApprovedInvestigational

    Interestingly, romiplostim's amino acid sequence is not similar to that of endogenous thrombopoietin. Romiplostim is produced by recombinant DNA technology in Escherichia coli. … Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl.

  8. Drug

    Fluvoxamine

    go.drugbank.com/drugs/DB00176
    ApprovedInvestigational

    It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. … Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.

  9. Drug

    Butoconazole

    go.drugbank.com/drugs/DB00639
    Approved

    Butoconazole is an imidazole antifungal used in gynecology.

  10. Drug

    Grepafloxacin

    go.drugbank.com/drugs/DB00365
    ApprovedWithdrawn

    Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States … Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections.

    Categories: Topoisomerase II Inhibitors